Logo

DTIL

Precision BioSciences, Inc.

DTIL

Precision BioSciences, Inc. • NASDAQ
$5.44 ▲ 6.46% (+0.33)
Market Cap $72.11 M
52w High $8.82
52w Low $3.61
Dividend Yield 0%
P/E -0.61
Volume 90.20K
Outstanding Shares 13.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13K ▼ $20.006M ▼ $-21.772M ▲ -167.477K% ▼ $-1.842 ▲ $-20.736M ▲
Q2-2025 $18K ▼ $21.199M ▼ $-23.52M ▼ -130.667K% ▼ $-2.13 ▲ $-22.466M ▼
Q1-2025 $29K ▼ $22.141M ▼ $-20.565M ▼ -70.914K% ▼ $-2.3 ▲ $-19.506M ▼
Q4-2024 $638K ▲ $25.484M ▲ $-17.745M ▼ -2.781K% ▲ $-2.51 ▼ $-16.596M ▼
Q3-2024 $576K $21.851M $-16.425M -2.852K% $-2.25 $-15.158M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $44.87M ▼ $93.51M ▼ $76.876M ▲ $16.634M ▼
Q2-2025 $62.242M ▼ $108.928M ▼ $74.874M ▼ $34.054M ▼
Q1-2025 $77.223M ▼ $124.411M ▼ $75.074M ▼ $49.337M ▼
Q4-2024 $86.312M ▼ $136.388M ▼ $79.995M ▼ $56.393M ▼
Q3-2024 $101.202M $153.258M $88.392M $64.866M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.772M ▲ $-15.27M ▲ $17K ▲ $1.659M ▼ $-17.372M ▼ $-15.27M ▲
Q2-2025 $-23.52M ▼ $-20.271M ▼ $-12K ▲ $5.3M ▼ $-14.981M ▼ $-20.273M ▼
Q1-2025 $-20.565M ▼ $-19.052M ▼ $-314K ▼ $10.687M ▲ $-8.679M ▲ $-19.366M ▼
Q4-2024 $-17.745M ▼ $-18.683M ▼ $-97K ▼ $5.92M ▲ $-12.86M ▼ $-18.78M ▼
Q3-2024 $-16.425M $-5.912M $-64K $3.733M $-2.243M $-5.976M

Revenue by Products

Product Q4-2021Q1-2025Q2-2025Q3-2025
Collaboration and License
Collaboration and License
 $0 ▲$0 ▲$0 ▲$0 ▲
Operating Segments
Operating Segments
 $0 ▲$0 ▲$0 ▲$0 ▲
Food Segment
Food Segment
 $0 ▲$0 ▲$0 ▲$0 ▲
Therapeutics Segment
Therapeutics Segment
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement The company is still at an early, pre-commercial stage, with only modest collaboration and milestone revenue and no recurring product sales yet. Over the past few years, revenue has been small but generally moving in the right direction. Operating results have historically been meaningfully negative as R&D and overhead far outweigh income. Most notably, the most recent year shows a small accounting profit and positive EBITDA, suggesting either tight cost control, one-time items, or partnership income helped flip results on paper. Even so, the underlying business remains that of a loss-making clinical-stage biotech rather than a mature, profitable enterprise.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and other liquid assets, which is typical for a clinical-stage biotech without commercial products. Cash levels peaked a couple of years ago and have since declined, reflecting ongoing spending and cash burn, but they still represent a large share of total assets. Debt remains low and fairly stable, which limits financial leverage risk but also means the company relies heavily on equity and partnerships for funding. Shareholders’ equity dipped in the recent past and then recovered in the latest year, likely due to the swing to reported profitability and/or capital actions. The reverse stock split in early 2024 is a structural change in share count rather than a fundamental change in value, but it underscores the company’s small size and past share price pressure.

Cash Flow

Cash Flow Despite the recent accounting profit, the company continues to use cash rather than generate it. Operating cash flow has been consistently negative, reflecting ongoing spending on R&D and corporate infrastructure in excess of cash inflows from partners. Capital spending is minimal, so almost all of the cash burn is driven by operating activities rather than large investments in physical assets. Free cash flow has been negative every year, indicating the business is not yet self-funding and still depends on its cash reserves, collaborations, and potential future financings. The key question is how long the current cash can support the pipeline before further external funding is needed.

Competitive Edge

Competitive Edge Precision sits in a highly competitive and fast-moving gene editing field, going up against much larger and better-funded players built around CRISPR and other technologies. Its main differentiator is the proprietary ARCUS platform, which aims to offer high precision, smaller editing machinery for easier delivery, and strong gene insertion capabilities. Early clinical signals in hepatitis B and partner-led programs provide some validation, but these are still early-stage and must be confirmed in larger studies. Strategic collaborations with big pharma partners add credibility, technical resources, and some funding support, partially offsetting the scale disadvantage. Overall, the company has a focused niche with clear technical claims, but it operates in an environment with intense scientific, regulatory, and competitive uncertainty.

Innovation and R&D

Innovation and R&D The business is fundamentally an R&D platform built around the ARCUS gene editing technology, with most resources directed toward developing and validating this toolkit. The lead internal program targets chronic hepatitis B with a potential one-time, curative-style approach that aims to eliminate the underlying viral DNA. Additional partnered programs in diseases like Duchenne muscular dystrophy and metabolic disorders showcase the platform’s flexibility for both gene correction and gene insertion. Past work in allogeneic CAR-T therapies has given the company clinical experience and safety data, even though the focus has shifted more squarely to in vivo gene editing. A strong patent estate, with protection for key assets extending well into the next decade, is a central part of its innovation strategy and potential long-term moat—provided the clinical programs succeed.

Summary

Precision BioSciences is a small, clinical-stage biotech whose story is driven more by science and partnerships than by current financial performance. Financially, it has modest revenue, a recent accounting improvement, but ongoing cash burn and reliance on its cash balance and external funding. Scientifically, it is betting on the ARCUS platform as a differentiated alternative to mainstream gene editing tools, with early but still preliminary clinical validation. Collaborations with larger pharmaceutical companies partially de-risk the story and offer external validation, yet the company operates in a crowded, rapidly evolving space with significant clinical and regulatory risks. The overall picture is of a high-innovation, high-uncertainty platform company that is still in the proving phase, both in the clinic and in its path to sustainable economics.

NEWS

November 19, 2025 · 7:01 AM UTC

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Read more

November 10, 2025 · 6:12 PM UTC

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Read more

November 10, 2025 · 5:21 PM UTC

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Read more

November 3, 2025 · 7:01 AM UTC

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

October 31, 2025 · 7:01 AM UTC

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Read more